HLF at a glance
HERBALIFE LTD. (HLF, SEC CIK 1180262) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 31, 2026 and Form 4 insider filings as recently as August 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), HERBALIFE LTD. (HLF) reported revenue of $5.0 billion (up 0.9% from FY2024) and net income of $228.3 million. Diluted EPS was $2.20.
- As of June 30, 2026, 30 institutional investment managers tracked by SignalX reported holding HERBALIFE LTD. (HLF) shares worth $674.1 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by L'Helias Sophie on June 4, 2026 of 1,200 shares at $11.31 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $5.0B
- +0.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 30 funds
- $674.1M · −1 vs prior quarter
- Latest 8-K
- Aug 31, 2026
- Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Global health and wellness company using direct-selling model with independent Members distributing nutrition and lifestyle products in 95 markets
- New products: Launched HL/Skin skincare line in Europe/Africa, Protein Gelato in Brazil, MultiBurn metabolic supplement and Life I/O™ healthy lifespan brand in North America
- Strategic shift: Expanded targeted "daily consumption" models like Nutrition Clubs and Member-led wellness programs to increase customer engagement and loyalty
- Quantitative metric: 6.4 million total Members worldwide with approx. 750,000 sales leaders as of Dec 31, 2025; 70.3% sales leader retention rate for 2026 re-qualification
- Noteworthy fact: Unique China business model employing independent service providers due to regulatory restrictions on multi-level marketing, with tailored compensation system
Risk Factors
- Regulatory risk: Compliance with FTC Consent Order, failure could materially harm business and financial results
- Geopolitical risk: China market requires modified business model amid political and legal uncertainties
- Supply chain risk: Dependence on manufacturing facilities and third-party suppliers for quality and timely product supply
- Competitive risk: Competition from more resourceful direct-selling organizations and emerging weight management drug technologies
- Financial risk: Obligations under convertible notes could dilute shares and depress share price upon conversion
Management Discussion & Analysis
- Revenue $5,037.5M, up 0.9% YoY (+$44.4M); local currency sales up 2.5%
- Operating margin 9.6% in 2025 vs 7.7% in 2024; net income $228.3M, down 10.2% YoY due to $132.2M higher income taxes
- Best segment: Primary Reporting Segment net sales $4,758.4M (+1.3%), contribution margin 42.8%; worst: China net sales down 6.2% to $279.1M, contribution margin +1.6%
- No explicit cash flow or capital allocation $ disclosed in excerpt; prior year included $10.5M loss on debt extinguishment
- Management outlook highlights ongoing inflation, FX risk, geopolitical conflicts impacting costs/pricing; focus on Member tools, new product launches, and digital platform rollout (Pro2col) in 2026
AI summary of the HLF 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $1,326.8M, up 5.4% YoY from $1,259.1M
- Net margin (2.0%) vs 3.9% YoY; operating margin 9.7% vs 10.5%
- Best region Asia Pacific revenue $470.6M, up 15.2% YoY
- Worst region China revenue $60.4M, down 24.5%; contribution margin $21.2M, down 25.9%
- Headwinds: inflation, tariffs, foreign exchange, energy costs, and geopolitical conflicts; additional pricing actions under review
Risk Factors
- No material risk-factor changes from 2025 10-K, except debt references updated after April 2026 refinancing
- Refinancing risk: 2024 Credit Facility and 2029 Secured Notes replaced by 2026 Credit Facility and 2033 Secured Notes
- Covenant risk: 2026 Credit Facility requires financial-ratio and financial-condition compliance
- Default risk: accelerated debt could trigger cross-defaults and foreclosure on substantially all domestic loan-party assets
- Liquidity risk: revolving-credit lenders may terminate undrawn borrowing commitments after default
AI summary of the HLF 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Stephan Gratziani transitioning from Chief Executive Officer effective October 31, 2026
- CEO succession creates near-term leadership uncertainty for strategy and operating execution
Item 2.02: Results of Operations and Financial Condition
- Exhibit 99.1 furnished under Item 2.02, likely containing Herbalife’s fiscal-year 2026 results
- Investor-relevant financial figures and management commentary reside in the attached exhibit
Item 7.01: Regulation FD Disclosure
- Standard Regulation FD disclaimer limiting Exchange Act Section 18 liability
- Disclosure not incorporated into other SEC filings unless expressly referenced
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CFO John DeSimone retiring December 31, 2026, creating a planned finance leadership transition
- Scott Schaefer becoming CFO January 1, 2027, after serving as Senior Vice President, Finance and Transformation since November 2025
Item EX-99.1: Item EX-99.1
- Q2 net sales $1.327B, up 5.4% YoY, marking the fourth consecutive quarter of reported growth
- Adjusted EBITDA $166.6M, while GAAP net loss $(26.3)M reflected a $94.6M debt-extinguishment charge
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 references Exhibit 99.1, which contains the fiscal-year 2026 results
- Exhibit 99.1’s financial results are furnished, not filed under Exchange Act Section 18
Item 5.07: Submission of Matters to a Vote of Security Holders
- All 11 director nominees elected, preserving board continuity through fiscal 2026
- Des Walsh faced strongest opposition, with 7,698,500 votes against
Item 7.01: Regulation FD Disclosure
- Standard Regulation FD disclaimer limiting liability under Section 18 of the Exchange Act
- Disclosure not incorporated by reference into other filings unless expressly referenced
AI summaries of HLF 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HLF
Don't miss the next HLF filing
- Alerts as it files. A push when HLF files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HLF, by share count.
- Ask anything. An AI agent that reads every HLF filing and answers with sources.
HLF alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Lamberti Frank | F | Aug 4, 2026 | 1,710 | $12.80 |
| L'Helias Sophie | Buy | Jun 4, 2026 | 1,200 | $11.31 |
| Hicks Troy | Sell | May 19, 2026 | 10,000 | $12.32 |
| Hicks Troy | M | May 18, 2026 | 17,481 | - |
| Hicks Troy | F | May 18, 2026 | 58,064 | $12.59 |
| Hicks Troy | M | May 18, 2026 | 65,789 | $9.58 |
| Hicks Troy | Sell | May 18, 2026 | 38,377 | $12.93 |
| Hicks Troy | M | May 18, 2026 | 17,481 | $8.31 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $5.0B | $5.0B |
| Gross Profit | - | $3.9B | $3.9B |
| Operating Income | - | $385.9M | $481.0M |
| Net Income | - | $254.3M | $228.3M |
| Gross Margin | - | 77.9% | 77.9% |
| Op. Margin | - | 7.7% | 9.5% |
| Net Margin | - | 5.1% | 4.5% |
| Balance Sheet | |||
| Total Assets | $2.8B | $2.7B | $2.8B |
| Equity | -$1.1B | -$801.1M | -$515.1M |
| ROE | - | -31.7% | -44.3% |
| Per Share | |||
| EPS | - | $2.50 | $2.20 |
| Cash Flow | |||
| Operating CF | - | $285.4M | $333.3M |
| CapEx | - | $122.0M | $80.4M |
Source: XBRL data in HERBALIFE LTD. (HLF)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate HLF share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 30 | $674.1M |
| Q1 2026 | 31 | $811.9M |
| Q4 2025 | 27 | $752.5M |
| Q3 2025 | 27 | $461.8M |
| Q2 2025 | 28 | $464.1M |
| Q1 2025 | 25 | $397.9M |
| Q4 2024 | 21 | $241.2M |
| Q3 2024 | 16 | $138.4M |
- BlackRock+549.3K (+7%)
- JPMorgan Chase & Co+310.2K (+205%)
- Citigroup+218.9K (+19%)
- State Street Corp+124.0K (+5%)
- Vanguard Portfolio Management LLC+106.2K (+2%)
- FMR LLC (Fidelity)−2.74M (-52%)
- Goldman Sachs Group−1.35M (-43%)
- Renaissance Technologies LLC−475.3K (-9%)
- Morgan Stanley−217.3K (-23%)
- Prudential Financial−210.4K (-76%)
- Mangrove Partners−12.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 205 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HLF filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 31, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Jun 4, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| SC 13G | May 6, 2026 | - | - | |
| 4 | May 5, 2026 | - | - | - |
| 4 | May 5, 2026 | - | - | - |
| 4 | May 5, 2026 | - | - | |
| 4 | May 5, 2026 | - | - | - |
| 4 | May 5, 2026 | - | - | - |
Related Health Care companies
- CAH · Cardinal HealthWholesale-Drugs, Proprietaries & Druggists' Sundries
- COR · CencoraWholesale-Drugs, Proprietaries & Druggists' Sundries
- MCK · McKesson CorporationWholesale-Drugs, Proprietaries & Druggists' Sundries
- NUS · NU SKIN ENTERPRISES, INC.Wholesale-Drugs, Proprietaries & Druggists' Sundries
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
HLF SEC filings: frequently asked questions
Which institutions hold HLF stock?
As of June 30, 2026, the largest HERBALIFE LTD. (HLF) holders among the 13F filers tracked by SignalX were Baupost Group ($121.8 million), BlackRock ($110.1 million), Vanguard Portfolio Management LLC ($81.4 million), Renaissance Technologies LLC ($66.1 million), Vanguard Capital Management LLC ($58.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HLF's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), HERBALIFE LTD. (HLF) reported revenue of $5.0 billion (up 0.9% from FY2024) and net income of $228.3 million. Diluted EPS was $2.20. The figures come from the XBRL data in the 10-K.
What are the main risks in HLF's latest 10-K?
In the 10-K filed February 18, 2026, HERBALIFE LTD. (HLF) flagged: Regulatory risk: Compliance with FTC Consent Order, failure could materially harm business and financial results. Geopolitical risk: China market requires modified business model amid political and legal uncertainties. (AI summary of the Risk Factors section.)
What did HLF report in its latest 8-K?
HERBALIFE LTD. (HLF) filed an 8-K on August 31, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Stephan Gratziani transitioning from Chief Executive Officer effective October 31, 2026.
What are the latest HLF SEC filings?
HERBALIFE LTD. (HLF) filed its latest 10-K annual report on February 18, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 31, 2026 and a Form 4 insider filing on August 5, 2026.
What is HLF's SEC CIK number?
HERBALIFE LTD. (HLF)'s SEC Central Index Key (CIK) is 1180262. EDGAR lists every HLF filing under that number.
Ask anything about HLF
The research agent reads HLF's filings, financials, insider trades and 13F holders, then answers with sources.